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Consistencies and Inconsistencies
Underlying the Quantitative Assessment of
Leukemia Risk from Benzene Exposure
by Steven H. Lamm,* Anthony S. Walters,*
Richard Wilson,t Daniel M. Byrd,t and Hans Grunwald§
This paper examines recent risk assessments for benzene and observes a number ofinconsistencies within
the study and consistencies between studies that shouldeffect the quantitative determination ofthe risk from
benzene exposure. Comparisons across studies show that only acute myeloid leukemia (AML) is found to be
consistently in excess with significant benzene exposure. The data from the Pliofilm study that forms the
basis ofmostquantitative assessments reveal that all the AMLcases came from only one ofthe three studied
plants and that all the benzene exposure data came from the other plants. Hematological data from the 1940s
from theplant from which almost all ofthe industrial hygiene exposure data comedo not correlate well with
the originally published exposure estimates but do correlate well with an alternative set of exposure esti-
mates that are much greater than those estimates originally published. Temporal relationships within the
study are not consistent with those ofother studies. The dose-response relationship is strongly nonlinear.
Other data suggest that the leukemogenic effect ofbenzene is nonlinear and may derive from a threshold
toxicity.
Introduction
Quantitative assessments ofthe carcinogenic (leukemo-
genic) risk from benzene exposure have been of regula-
tory importance since the U.S. Supreme Court(1) in 1980
overturned the 1978 OSHA (Occupational Safety and
Health Administration, US) benzene standard, primarily
because OSHA did not demonstrate that a significant risk
ofleukemia existed under the previous benzene standard.
Quantitative risk assessment has subsequently become
the standard method used by regulatory agencies to es-
timate the cancer risk under a specific exposure scenario.
The process ofquantitative risk assessment attempts to
discover underlying uniformity and continuity among
numerous studies that each reflect different aspects of
the risk relation between exposure and disease-each
with its own deviance from the "truth." The sources and
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magnitude ofthese deviances, while often unclear, can be
shown and assessed more clearly by asking similar criti-
cal questions ofeach study to define clearly the underly-
ingassumptions andby testingthose underlyingassump-
tions. This paper deals with the concept of consistency
among the studies that generally support the concept of
an association between benzene exposure and excess risk
ofleukemia andwithin the studies critical to the quantita-
tive assessmentofthat risk. Although thelargest studies
relating benzene and cases ofleukemia are those ofAk-
soy (2) in Turkey(51 cases), Vigliani(3) in Italy(24 cases),
and Yin (4) in China(30 cases), the largest United States
study (9 cases) which was conducted by the National In-
stitute for Occupational Safety and Health (NIOSH) (5)
serves as the primary basis for the quantitative assess-
ment ofleukemia risk from benzene exposure. The find-
ings ofthe larger studies are compared with the NIOSH
study for consistency offindings across studies, and the
NIOSH study is examined in detail laterin this paperfor
consistency within the study.
The basic classiflcation of leukemias is reviewed as a
prelude to a review of the types of leukemia noted in
studies ofbenzene exposed workers. The critical NIOSH
study(6)is thenreviewedwith respect to the relationship
between the leukemia cases and the benzene exposure
datapresented in the paper. Finally, thispaperconsiders
some of the consequences of these observations on theLAMM ETAL.
theoretical shape of the dose-response curve between
benzene and leukemia.
Observations from the Literature on
Benzene and Leukemia
Classification of Lymphomas and
Leukemias
In the International Classification of Diseases
(ICD-9-ICM) (6), leukemias fit in the general class called
Neoplasms ofthe Lymphopoietic and Hematopoietic Tis-
sues (ICD numbers 200 to 208) as seen in Table 1. The
basic hematopoietic tissues, found in the bone marrow,
are the precursors ofblood cells. Oneprimary cell line is
the lymphoid line ofcells, which originates in areas such
as the lymphnodes andforms cancers such aslymphomas
(solid tumors), multiple myelomas (cancer ofthe plasma
cell), andlymphoid leukemias, oftenwith invasion offree
cells in the blood orproliferating in the bone marrow. A
secondline, themyeloid line(frommyelos, meaningmar-
row) forms the leukemias known as myelogenous (mean-
ing originating from the marrow cells) or asgranulocytic
(since their cytoplasm shows granules when fixed and
stained).
Within the classification of leukemia, lymphocytic
leukemias derive from lymphoid orlymphopoietic tissue;
myelocytic (and monocytic) leukemias derive from mye-
loid or hematopoietic tissue. Each cell type further
differentiates into two different types ofleukemiabased
on whether the dominant cell is immature (acute) or ma-
ture (chronic). Thus, the fourmajortypes ofleukemia are
acute lymphoid leukemia (ALL), chronic lymphoid leuke-
mia (CLL), acute myeloid leukemia (AML), and chronic
myeloid leukemia (CML).
The ICD numbers(Table 1)reflect distinctions that can
generally be made both in a medical diagnosis and in
differences indevelopment ofthe cell types. Theseleuke-
Table 1. Classification oflymphoma/leukemia: Malignantneoplasms
ofthe lymphatic and hematopoietic tissue (6).
International Classification
Type of Diseases
Lymphoma
Non-Hodgkins 200
Reticulosarcoma 200.0
Lymphosarcoma 200.1
Hodgkins 201
Others and mixed (Hairy cell,
histiocytosis) 202
Multiple myeloma (plasma cell origin) 203
Leukemia
Lymphoid 204
Acute (ALL) 204.0
Chronic (CLL) 204.1
Myeloid 205
Acute (AML) 205.0
Chronic (CML) 205.1
Monocytic, etc. 206
Other 207
Unspecified 208
mias also differ in characteristics of the age of the pa-
tients, their causes, their clinical patterns, and their re-
sponse to different therapeutic interventions. Each type
has a number ofvariants. The acute myeloid leukemias
(AML) can be further subclassified (7) as a)myeloblastic,
b) promyelocytic (APL), c) myelomonocytic (AMML),
d) monoblastic (AMoL), e) erythroleukemia (AEL), or f)
megakaryoblastic (AMegL). Occasional cases may seem
to cross definitionboundaries, other cases maybe unclas-
sifiable, and further cases may fall outside of each defi-
nition. Nonetheless, the four major types of leukemia
(ALL, CLL, AML, and CML) account forthe majority of
leukemia cases.
The four major classes of leukemias are generally
regarded as distinct cancerous states. It would contradict
our present understanding ofcancerfor aparticular car-
cinogen to produce one type ofleukemia in some people
and another type in others, although it is not impossible
to imagine thispossibility. For example, a qualitative dif-
ference in metabolism could be demonstrated between
two groups. In the case ofbenzene, no evidence exists of
major differences in metabolism.
Association of Benzene and Leukemias
Clinical and epidemiolQgical evidence consistently indi-
cate that acute myeloid leukemia(AML) and its variants
(alternatively called acute nonlymphocytic leukemias, or
ANLL) can be causedby benzene exposure. While some
studies have implicated other types ofleukemia or even
lymphomas, onlyAML and itsvariants have consistently
been seenin excess ingroups ofworkers with excessben-
zene exposure. Figures 1 through 6 show by type of
leukemia the distribution of the cases associated with
benzene exposure from modern published studies with
five or more leukemia cases. In almost all, AML
markedly predominates. Goldstein (8) reviewed the evi-
dence on benzene-associated leukemia in 1977 and con-
cludedthatonlyAML anditsvariantshadbeen definitely
associated with benzene exposure; in every other type of
leukemia, the evidence was not definite. Studies since
that time have supported his conclusion.
Vigliani reported originally in 1964(9) and again in 1976
(3) on the benzene and leukemia experience ofItalian oc-
cupational medicine clinics (Fig. 1). Twenty-four of 24
cases of leukemia in benzene-exposed workers were
AML. Aksoyreported originallyin 1974(10)andagainin
1985 (2) on the experience of Turkish shoemakers and
leatherworkers with benzene and leukemia (Fig. 2).
Forty-three of 51 cases of leukemia were AML. The
NIOSH study ofthe experience ofOhio Pliofilm rubber
workers at twolocations withbenzene andleukemia(Fig.
3)wasreported originally in 1977by Infante etal. (11)and
updated and extended in a 1987 report by Rinsky et al.
(5). Six of9 cases ofleukemiawere AML. The experience
of a U.S. chemical company with benzene and leukemia
(Fig. 4) was reported originally in 1978, by Ott et al. (12),
and updated in a 1986 report by Bond et al. (13). Five of
five cases of leukemia were AML. Recently, Yin (4)
reportedthe experience ofaChineseindustrial commune
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with benzene and leukemia (Fig. 5). Twenty of thirty
cases ofleukemia were AML. The only exception to the
observation that two-thirds or more ofleukemias associ-
ated with benzene are AMLs was theWong et al. report
(14). Wong studied workers occupationally exposed to
benzene in U.S. chemical plants and reported no AML
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FIGURE 1. Percent distribution of Vigliani's benzene leukemia cases
(n = 24) (3).
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FIGURE 2. Percent distribution of Aksoy's benzene leukemia cases
(n = 51) (2) and nonbenzene leukemia cases (n = 50) (11).
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FIGURE 3. Percent distribution of Rinsky's benzene leukemia cases
(n = 9) (5).
100
90
p 80
70
r 60
c 50
e 40
n 30
t 20
10
0
ALL CLL AML CM- Other
FIGURE 4. Percent distribution of Bond's benzene leukemia cases
(n = 5) (13).
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FIGURE 5. Percent distribution of Yin's benzene leukemia cases
(n = 30) (4).
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FIGURE 6. Percent distribution of Wong's benzene leukemia cases
(n = 7) (14).
case among the seven leukemia cases observed (Fig. 6).
Based on the experiences of other benzene-exposed
groups, at least four cases ofAML would have been ex-
pectedamongthe seven leukemia cases. There are anum-
ber of other observations from the Wong et al. study
where the results are different from other benzene
studies. No case of leukemia was observed in their
nonbenzene-exposed workforce.
Figure 3 presents the cell type distribution ofleukemia
cases in the most recent report of the NIOSH study of
the Ohio Pliofilm rubberworkers (5). Again, AML is the
most common type. Six of the nine cases of leukemia
reported in the study were AML. Five cases reported
were myeloblastic and the sixth was AMoL. The pattern
thatagain stands outis the dominance ofAML amongthe
leukemias of benzene-exposed workers.
There are few studies that provide comparative data
on the proportion ofleukemias expected to be AML in a
nonbenzene-exposed workerpopulation. Mostpopulation
studies show that AML accounts for about one-third of
all leukemias, typically rangingfrom 20 to 40%. The only
direct comparison group is found in the study by Aksoy
(2), which reported the leukemia types of 50 cases of
leukemia in men seen in the same clinics but lacking
known benzene exposure. He reported about equal num-
bers of each of the 4 types of cases (Fig. 2). Aksoy's
studies ofTurkish shoemakers were interestingbecause,
while professor at the university hematology clinic in
Istanbul, he was able to separate out 51 leukemia cases
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in workers with benzene exposure and 50 leukemia cases
in persons without benzene exposure. For those cases
that were benzene associated, AML prevailed (84%). For
those not exposed to benzene, AML represented only
28% of the leukemia cases. For the nonbenzene-related
background leukemias, Aksoy demonstrated arelatively
equal representation of AML, ALL, CML, and CLL.
AML is the only type that stood out in excess amongthe
benzene-exposed cases compared to the nonbenzene-
exposed cases (see Fig. 3). Thus, the studies ofbenzene
workers, with 65 to 100% of their leukemia cases diag-
nosed as AML, quite likely represent an increased risk
of AML.
The six studies described present a total of 126 leuke-
mia cases amongbenzene exposed workers. The percent-
age distribution of these cases by type of leukemia is
shown in Figure 7, alongwith expectedpercentilesbased
on 1978 US Leukemia Mortality data(20,21). There is lit-
tle exposure information within these studies to group
the workers into exposure categories other than the
gross category of occupationally exposed to significant
amounts of benzene, significantly great enough to be
described in the literature as benzene exposed. Figure 7
reveals that when the cases from all six studies are
viewedtogether, only AML stands out inmarked excess
above the others. This isthe epidemiologicalbasisforthe
conclusion that the acute myeloid leukemias are the only
leukemias found in significant excess with significantben-
zene exposure. Thus, we propose that the distribution of
AML among benzene exposed persons should serve as
the basis of epidemiological and risk analysis.
We believe estimations of the risk of leukemia from
benzene exposure should be based on the AML data,
since this neoplastic disease alone has been shown to have
an association with benzene exposure. It would be inap-
propriate to extrapolate the risk ofAML to all leukemias
when the risk appears to bebiologically specific to AML.
In studies where types ofleukemia are not stated, ana-
lyses may provisionally have tobe based on allleukemias,
but specific diagnostic datashould be obtained before the
data are used in risk analysis. Some risk assessments
have failed to compare the risks ofthe same disease be-
tween different studies.
Exposure definition and documentation have generally
been the weakest aspect ofrisk assessment. Essentially,
only AML is attributable to benzene exposure and other
types of leukemia are not. The probability of benzene
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FIGURE 7. Percent distribution of benzene leukemia cases from six
studies (n = 126)(13,14) and ofU.S. leukemia deaths, ages 15-74, 1978
(20,21).
causing other leukemias is low, and may be zero. Some
scientists disagree. They point to some studies where a
nonsignificant excess of CML may be associated with
benzene exposure, but they agree that this is not a con-
sistent result. In order to believe that benzene causes
CML, one must both explain the lack of consistency be-
tween and within studies, and reject the assumption that
agiven carcinogen producesthe same cancerin allpeople.
Risk Analysis of Benzene and
Leukemia
The Ohio Pliofilm study (11) conducted initially by
NIOSH through June 1975, reported the leukemia mor-
tality of some grotips of workers employed on the wet
side ofthe benzene-using Pliofilm manufacturingprocess
at three rubberplants in Ohio duringthe 1940s. Pliofilm
was made using natural rubber, processing it by adding
benzene to create rubber hydrochloride solution, and
eventually spreading the resultant solution on a con-
veyor. The benzene was evaporated and recovered. A re-
cent update ofthis study(6) extended the studygroup to
include workers assigned to these areas at the three
plants through 1965. The updated study reported the
deaths from leukemia and lymphomas that occurred
through 1981. Table 2 lists these leukemia and multiple
myeloma cases as presented by the authors with the es-
timated cumulative benzene exposure calculations in part
per million-years.
Plant History
Plant 1 at location 1 (St. Marys, OH) was established
in 1939 and continued manufacturing Pliofilm until 1976.
Plant 2A at location 2 (Akron, OH) commercially
produced Pliofilm from 1936-1937 through 1949, and
plant 2B, also at location 2, produced Pliofilm from 1949
until 1965. Itis asserted thatthe exposures from Pliofllm
process at each ofthe three plants were identical. With
the exception ofone reportfromplant2B, allbenzene ex-
posure measurements came from plant 1. No exposure
data are known for plant 2A. Since exposure data are
only presented forthe plant at location 1, the equivalency
of exposure has to be accepted as a matter of faith.
Leukemia Mortality Analysis
Table 3 presents the same data as Table 2, but or-
ganized by plant location. These data are unusual. The
two locations that are considered to be identical in terms
of process and benzene exposure have distributions of
cases that are entirely different with respect to the only
type of leukemia (AML) consistently found in excess
amongbenzene-exposed workers. Ail ofthe AML cases
came from one location (plant 2A, where no benzene ex-
posure data are available), while no cases ofAML were
diagnosed among the workers at plant 1 and 2B, where
some benzene exposure data are available.
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All the cases ofAML occurredin workers hired atplant
2A prior to 1945, a group observed for more than 37
years. Only one member ofthis group has died ofAML
since 1961. None ofthe workers hired into Plant 2A from
1945 to 1949 or into Plant 2B from 1949 to 1965 has been
reported to have any type ofleukemia in spite of 16 to 37
years of follow-up. None ofthe workers hired into plant
1 from 1939 to 1965 has been reported to have AML, al-
though the follow-up period has ranged from 16 to 42
years. The relative risk of dying ofAML during the first
half of the period of observation was markedly greater
than that of dying during the second half.
The cohort ofpeople from plant 2A is incomplete. The
personnel records from that location prior to 1945 are
missing, and the only people whose records of employ-
ment exist prior to 1945 are those people who were hired
prior to 1945 and continued working past 1945. It is
noteworthy to observe that among the cohorts for whom
employee rosters are complete (Akron 1945+ and St.
Marys 1940+), there is no known case ofAML. Thus, all
AML cases appear to be in the employment prevalence
cohort, and none appear to be in the employment inci-
dence cohort. This would suggest that exposures prior to
1945 were critical.
Temporal Relationship
Latency is usually defined as the time interval from
first exposure to date of death. The AML cases in this
study reveal a range of 13.5 to 37 years since first ex-
posure (Table 3) with a mean latency of 20.5 years. This
is surprising, because AML secondary to other exposures
is usually associated with latencies in the range of 0.5 to
10 years, with typical latencies of approximately 2 to 5
years (17). The latency range of AML after chemother-
apy is generally 0.5 to 8 years and after radiotherapy is
generally 4 to 10 years; therefore, the latency range is
typically less than 10years. The time ofexposure to ther-
apy is generally well known; the time ofoccupational ex-
posure is more difficult to ascertain. The concept of
latency with respect to occupational exposures uses the
time of first exposure as a surrogate for the time of crit-
ical exposure. It may be that there are exposures subse-
quent to the initial exposure that are the inciting or crit-
ical exposures.
The latencies reported in the Rinsky et al. study (5) also
have long duration in comparison to data from other
benzene-exposed groups. Unlike the Rinsky study (5),
which shows a mean latency of20.5 years, the data of Yin
Table 2. Case list of leukemias and multiple myelomas (11).
Latency, Cumulative benzene
Case Location Diagnosisa years Year of death exposure, ppm-year
1 1 MoL 17 1958 49.99
2 1 CML 2 1950 0.10
3 2 AML 13.5 1958 259.5
4 2 AML 15.5 1960 498.23
5 2 AML 22 1961 478.45
6 2 AML 20 1961 639.84
7 2 AMoL 15 1957 98.55
8 1 ML 3.5 1954 10.16
9 2 AML 37 1979 252.66
10 1 MM 25.5 1980 19.5
11 1 MM 22.5 1963 0.11
12 1 PCS 24.5 1968 652.66
13 1 MM 26.5 1981 7.75
aMoL, monocyticleukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; AMoL, acute monoblastic leukemia; ML, myeloid leuke-
mia; MM, multiple myeloma; PCS, plasma cell sarcoma.
Table 3. Case list of leukemias and multiple myelomas ordered by location and by year of hire (11).
Latency, Cumulative benzene
Location Diagnosisa Year of hire years Year of death exposure, ppm-year
2 AML 1939 22 1961 478.45
2 AML 1941 20 1961 639.84
2 AMoL 1942 15 1957 98.55
2 AML. 1942 37 1979 252.66
2 AML 1944 13.5 1958 259.5
2 AML 1944 15.5 1960 498.23
1 MM 1940 22.5 1963 0.11
1 MoL 1941 17 1958 49.99
1 PCS 1943 24.5 1968 652.66
1 CML 1948 2 1950 0.1
1 ML 1950 3.5 1954 10.16
1 MM 1954 25.5 1980 19.5
1 MM 1954 26.5 1981 7.75
aAML, acute myeloid leukemia; AMoL, acute monoblastic leukemia; MM, multiple myeloma; MoL, monocytic leukemia; PCS, plasmacell sarcoma;
CML, chronic myeloid leukemia; ML, myeloid leukemia.
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(4)have an average latency of11 years. Further, the data
ofAksoy(2) have an average latency of9years. Thus, the
NIOSH data are also unusual with respect to AML
latency in comparison to other studies of benzene-
associated leukemias.
The temporal relationship between exposure and dis-
ease may also be examined on the basis ofthe time inter-
val between the date of last exposure and the date of
death or diagnosis. An analysis ofthe literature in 1980
showed that 80% ofbenzene-associated leukemia deaths
occurred no more than two years after their last benzene
exposure (18). The implication ofthese results is that the
risk of leukemia decreases with time after exposure,
which suggests that benzene may act at a later stage in
the carcinogenic process, perhaps through action on pro-
motion or disease progression.
The idea that benzene is not an initiator is consistent
with two otherfacts: benzene has not caused mutagenic
effects at the level ofbase-pair changes(transitions, short
deletions, frame shifts, and soforth)inappropriate short-
term tests, and benzene pancytopenia frequently pre-
cedes leukemia. The Chinese study (4) reported a leuke-
miariskratio of 1500 forbenzene-exposed workers with
pancytopenia in comparison with aleukemia riskratio of
5 to 10forthe total benzene-exposedworkforce. This ob-
servation suggests that pancytopenia maybe a necessary
precursor or threshold condition in order for benzene-
induced leukemia to develop subsequently.
Benzene Exposure Assumptions
Rinsky et al. (5) estimated the AML cases at location
2(plant2A) to have cumulative benzene dosesgenerally
of250 to 650ppm-yearswith amedian exposure estimate
of370ppm-years. Unlike the non-AML cases, none ofthe
AML cases had low cumulative benzene exposures. The
non-AML cases had a median exposure estimate of 10
ppm-years. There does not seem to be agradual increase
in frequency by dose, with some of the cases occurring
at lower doses and more at higher doses. Furthermore,
since there are no known industrial hygiene datafor any
plant prior to 1949, all ofthe benzene exposures assigned
to the leukemia cases atlocation 2 arebased onindustrial
hygiene data from location 1 and from data collected in
subsequent decades. As the authors state, "Benzene ex-
posure levels measured atlocation 1 were assumed to be
identical to exposure levels in corresponding areas atlo-
cation 2, when actual exposure measurements did not
exist" (5).
In Rinsky's exposure analysis, historical air sampling
datawere usedwhere available, and estimates based on
existingdata wereusedwhen no datawere available. The
industrial hygiene data referenced (5) were collected in
the 1950s, 60s, and 70s, and then extrapolated back in
order to estimate exposures in the 1940s. Most of the
samples were area samples ofunspecified duration, and
onlythe datafromthemid-1970s were8-hrtime-weighted
averages. Nonetheless, all the data appear to have been
used as 8-hr, time-weighted average personal exposure
measurements.
Most ofthe benzene exposures estimated for workers
in Pliofilm production occurred during the 1940s, when
minimal or no exposure datawere collected. The estima-
tion of cumulative benzene exposures for specific in-
dividuals is limited to the time they spent in Pliofilm pro-
duction and is markedly dependent upon the assumptions
used to develop their exposure estimates for the 1940s.
The workforces atthe two plants differed in theirpoten-
tial for exposure to benzene and other chemicals at non-
Pliofilmjob sites. Plants 2A and 2B were part ofa large
industrial tire-building complex, andplant 1 wasisolated
in a small town in southern Ohio. Furthermore, the as-
sumptions made regarding exposure levels in the Pliofilm
operations in the 1940s are in dispute.
Rinsky et al. (5) assumed that for a given job the ex-
posure levels were constant backward over time unless
specific data indicated otherwise. In other words, the ex-
posure levels were assumed to be the same both during
the periods for which exposure data existed and during
priorperiods forwhich no data existed. Thus, ifthe only
data for a specific job produced an estimate of 15 ppm
when measured in 1976, they assumed that exposure in
thatjob in 1945 was also 15 ppm. While this procedure
might appear to be reasonable as a first approximation
in aretrospective study, alternatives exist to the assump-
tion that exposure levels did not change. Other alterna-
tives might include the assumption that the exposure
level continued at a certain measured level until observed
to be lower, orthatthe decrease (orincrease) in level pro-
gressed uniformly from one period of measurement to
another.
Crump and Allen (19) developed an alternative ex-
posure assumption in ananalysis ofthe industrial hygiene
data in a report for OSHA. Crump and Allen estimated
both a cumulative benzene exposure amount and a max-
imum or peak intensity benzene exposure level for each
ofthe employees in Pliofilm production. To calculate or
estimate exposure levelsforjobs duringtime periodsfor
which no data existed, they calculated all exposure data
for aparticularjob as a percentage ofthe allowable level
atthat time and then appliedthat percentage(orpropor-
tion) to each time period. Thus, ifthe data in 1976 indi-
cated that the average exposure to benzene in aparticu-
lar department was 15 ppm, i.e., 1.5 times the 10 ppm
standard in effect in 1976(15 ppm = 1.5 x 10 ppm), then
the benzene exposure in that same department in 1945
was assumed to be 1.5 times the 100 ppm standard in ef-
fect in 1945 (i.e., 1.5 x 100 ppm = 150 ppm). It is impor-
tant to remember that the benzene exposure standard
dropped from a maximum allowable concentration (MAC)
of 100 ppm in 1940 to a level of 50 ppm (8-hr time-
weighted average, TWA) in 1947, to a level of 35 ppm
(8-hr TWA) in 1948, to 25 ppm in 1957, and in 1969 to 10
ppm. In 1987, the standard (20) was lowered to 1 ppm,
based to a considerable extent on the NIOSH report. As
the Crump andAllen exposures were related to the stan-
dards ofthe time, the benzene exposure estimates forthe
early years were much greater in the Crump and Allen
analysis than in the Rinsky analysis.
An additional difference in the assumptions ofRinsky
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et al. (5) and ofCrump and Allen (19) is that the NIOSH
group limited their exposure calculations to Pliofilm
workers who worked on the wet side ofthe process (the
wet side was the area in the 1940s where benzene was
considered to be perceptible in the air), whereas the
Crump and Allenanalysisreported on exposure calcula-
tions for all identified Pliofilm workers, whetherassigned
to the wet side or to the dry side.
The determination of which set of exposure assump-
tionsprovidesthe more validbasis forcalculatingtherisk
cannot be based on information in these reports alone.
Neither Rinsky et al. (5) nor Crump and Allen (19) pro-
vide independent data thatpermit determining which of
the two assessments most likely represents the actual
benzene exposures. The reports by Kipen et al. (21,22)
analyzing hematology studies of the workers at plant 1
does provide some insight.
Because benzene causes hematotoxicity as demon-
stratedby reducedblood cell counts, complete blood cell
counts were frequently conducted on Pliofilm workers.
The hematology data from plant 1 were analyzed by
Kipen, Cody, and Goldstein (22), who identified the blood
counts ofindividualworkers, determined from theirwork
histories their job assignments at the time the blood
specimens were taken, and specified the benzene ex-
posure level that either Crump and Allen(19) or Rinsky
et al. (5) would have assigned them for that job at that
time. Analysis showed a correlation coefficient for the
white blood cell counts of0.72 with the Crump and Allen
exposure estimatesforthe years 1940 to 1948 and a corre-
lation coefficient of0.03 with the Rinsky et al. exposure
estimates for the same time period. Thus, with respect
to hematotoxicity, the exposure estimates ofCrump and
Allen better reflect the hematological status ofPliofilm
workers duringthe 1940s. Webelieve it is reasonable to
assume that exposure estimates that correlate bestwith
the evidence ofhematotoxicity in the same cohort would
provide the most reliable exposure estimates to use in a
quantitative riskanalysis, particularly ifbenzene-related
leukemia is found to develop from aprecursor condition
ofbenzene-related hematotoxicity.
Quantitative Risk Analysis
For developing aquantitative risk assessment forben-
zene based on the mortality data of the Ohio Pliofilm
study (5), dispute exists over which worker population,
which exposure estimates, and which leukemias should
be used.
The NIOSH studyby Rinsky et al. (5)limited the popu-
lation to the Pliofilmworkers who workedinthe wet side
section through 1965. Crump and Allen (19)used as their
study population all known workers in the Pliofilm oper-
ationthrough 1965, includingboth the workers from the
wet side andthe workersfromthe dry side ofthe Pliofilm
operation. We concur with Crump and Allen that for a
quantitative risk analysis the studied cohort should in-
clude allthoseinPliofilmmanufacture, andnotjustthose
from the wet side. Inclusion ofas full a spectrum of ex-
posure as feasible increases the robustness and reduces
the uncertainty in applications of the derived risk esti-
mate. Exclusion of the dry side workers specifically
diminishes the low end of the exposure spectrum.
Rinsky et al. assumed, in the absence ofexposure data,
that exposure over time was constant on an absolute
scale; Crump and Allen assumed, in the absence of ex-
posure data, that exposure over time was constant on a
relative scale, relative to the occupational benzene stan-
dard of the time. Rinsky et al. concentrated on the cu-
mulative benzene exposure; Crump and Allen explored
the interpretation of both the cumulative benzene ex-
posure estimates and the peak benzene exposure esti-
mates. We would have explored a number ofdifferent ex-
posure assumptions, as indicated, andfor both peak and
cumulative exposures. With respect to exposure data, we
would have given preference to the Crump and Allen as-
sumptions, based on the analysis by Kipen et al. (21) of
the hematology data at plant 1.
Both assessments used the exposure datafrom location
1 to serve as a surrogate measure ofexposure atlocation
2. Ifthebenzene exposure isthought tobe the critical de-
terminant of risk, we find it difficult to accept that the
benzene exposure levels at location 2, where all of the
AML cases occurred, could have been the same as the ex-
posurelevels atlocation 1, where no AML casesoccurred.
We would have reported the risk analysis ofeach location
separately.
Both Rinsky et al. and Crump and Allen incorporated
all leukemias in their analyses. We would have reported
separately the analysis ofriskofacute myeloidleukemia
(AML). Based on the observations in the larger studies
ofleukemia inbenzene-exposed workers, we believe that
evaluation of the risk of benzene-associated leukemia
should specifically target upon AML. The calculated risk
values would thus become more significant, both statisti-
cally and biologically.
The most appropriate studypopulation would have con-
sistedofall persons who everworkedinthe Pliofilm oper-
ation. Unfortunately, the personnel records no longer
existforpersons whoworkedinthe Pliofilm operation in
plant 2A andterminated theirPliofilm assignment prior
to 1945. Therefore, those individuals cannot be included
in the study population. In view of this exclusion, the
population is best analyzed as a combination of a cross-
sectional study cohort and an employment incidence co-
hort. Wewouldhave separately analyzedthe risksforthe
employment incidence cohort from that of the cross-
sectional cohort and have discussed the differences in ob-
servations.
Separating the analysis into multiple strata is a prob-
lem when only a few cases (6 AML, 2 CML, and 1 MoL)
ofleukemia have been observed. Nonetheless, it is impor-
tant to observe whether the cases (andthe risks) do con-
centrate within the most rigorously defined cohort or in
its periphery.
Graphical Risk Analysis
Figure 8 serves as an example ofan analytic model ex-
hibitingthe exposure circumstances necessary forthe de-
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FIGURE 8. Benzene-leukemia dose relationship by peak benzene level
(ppm) of Rinsky (5) for all known 1940-1965 Pliofilm workers.
velopment of a significant excess risk ofdisease mortal-
ity. As a model, the cumulative leukemia risk (using all
9 leukemia cases) with benzene exposure expressed by
peak exposure experienced by workers is presented for
sequentially higherpeak levels ofbenzene exposure. This
particulargraph shows peakbenzene exposurelevels ac-
cordingto Rinsky's (5) exposure assumptions. The cohort
is defined according to Crump and Allen's (19) criteria.
The three lines represent sequentially the cumulative
number of cases of leukemia observed, the cumulative
number ofcases ofleukemia expected, and the 95% lower
confidence limit of the observed number of leukemia
cases. A statistically significant excess ofleukemia cases
has been observed when the 95% lower confidence limit
isgreaterthan the cumulative expected. Itis notuntilthe
last two exposure levels are included that there is a sig-
nificant excess ofleukemia observed among the benzene
exposed workers. Thus, if the NIOSH assumptions of
Rinsky (5) are used, this occurs at a peak benzene level
greater than 40 ppm (Fig. 8). Ifthe exposure assumptions
of Crump and Allen (19) are used, a statistically signifi-
cant excess of leukemia cases is observed only when
workers with exposures above 250 ppm are included (Fig.
9).
Risk analysis for all leukemia classes based onboth the
exposure estimates and the cohort assumptions ofRinsky
(5) would lead to the conclusion that a significant excess
risk ofleukemia was not observed until the study popu-
lation included those with a peak benzene exposure of
greater than 20 ppm or an estimated cumulative benzene
exposure ofgreater than 250 ppm-years (Table 4). Simi-
lar analyses based on the exposure estimates of Crump
and Allen (19) and applied to all the studied workers at
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FIGURE 9. Percent observed/percent expected by type ofleukemia for
all six studies (2-4,6,13,14).
Table 4. Benzene exposure characteristics of excess leukemia
risk based on different assumptions ofstudy cohort and of
exposure parameters.
Study parameters Significant risk excess
Author Cohort Exposure Peak Cumulative
Rinksy (5) Wet side Linear > 20 ppm > 250 ppm-year
Total Linear > 40 ppm > 250 ppm-year
Wet side Proportional > 250 ppm > 250 ppm-year
Crump (19) Total Proportional > 250 ppm > 450 ppm-year
the plants lead to the conclusion that a significant excess
risk ofleukemia was not observed for those in the study
group who had an estimated peak benzene exposure of
less than250ppm oran estimated cumulative benzene ex-
posure of less than 450 ppm-years (Table 4). Assuming
that these exposures occurred over a 40-year worklife,
the Rinsky assumptions using this model would reach the
conclusion that a statistically significant leukemia risk
existed with peak benzene exposure over 20 ppm and a
worklife average exposure over 6 ppm (250 ppm-yrs/40
years = 6.25ppm). Similarly, the Crump assumptions us-
ingthe same model would conclude that a statistically sig-
nificant leukemia risk existed with peak benzene ex-
posure over 250 ppm and a worklife average exposure
over 11 ppm (450 ppm-yr/40 years = 11.25 ppm). Thus,
the determination as to whether the previous benzene
standard of 10 ppm included a significant leukemia risk
ismarkedly dependent upon the methodological assump-
tions made in analyzing the data.
Conclusions
Available data strongly support the conclusion that
AML canbe causedby excessive benzene exposure. This
is a consistent observation among all recent studies with
the exception of that ofWong (14).
There is no consistent evidence forproduction ofALL,
CML, or CLL by benzene exposure. A belief that ben-
zene causes CML would necessitate the proposition that
the same exposure causes different tumors in different
groups of people.
An examination ofthe two parts ofthe Pliofilm cohort
suggests a difference between the two plants in that
AML cases occurred at only one plant (2A) and only
among those already working in the plant prior to 1945.
One explanation consistent with the data is that the men
working in plant2Aprior to 1945 had amuch higherlife-
time benzene exposure than previously assumed and
more than those men working in plant 2A or 2B after
1945.
The overall data seem more consistent with the dose as-
sumptions of Crump and Allen than those of Rinsky et
al. The exposure estimates derivedfrom the Crump and
Allen assumptions correlate very well with the hemotox-
icity data from plant 1; the exposure estimates derived
fromthe Rinsky et al. assumptions do not. Therefore, the
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Crump and Allen estimates are more likely to provide a
better representation of workers' exposures.
The Rinsky et al. study shows a strong nonlinearity
with dose using either the Rinsky et al. (5) or the Crump
and Allen (19) exposure estimates. Furthermore, the risk
ratio does not appear to stay constant after a latent
period, but appears to fall with time.
The nonlinearity ofriskwith exposure dose, the obser-
vation ofpancytopenia prior to leukemia, and the latent
period are all consistent with leukemia as an indirect ef-
fect of benzene.
Ifthe data are to be usedfor quantitative assessment,
the analysis should be limited to AML cases, the sur-
rogate nature ofthe exposure data should be noted, and
the observation thatthe excess cases ofAML all have at-
tributed cumulative benzene exposures of250 to 650ppm-
years should be prominently observed.
We propose that future assessments of leukemic risk
from benzene exposure be based on the distribution pat-
tern ofAML alone, as that is the sentinel neoplastic dis-
ease associated with excess benzene exposure. This con-
cept is consistent with the assessment ofGoldstein (8)and
with the studies of Vigliani (3), Aksoy (2), Rinsky (5),
Bond (13), and Yin (4).
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